On Friday, BridgeBio Pharma Inc (NASDAQ: BBIO) opened higher 0.30% from the last session, before settling in for the closing price of $33.74. Price fluctuations for BBIO have ranged from $21.62 to $39.54 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 574.82% over the past five years. Company’s average yearly earnings per share was noted -7.21% at the time writing. With a float of $160.65 million, this company’s outstanding shares have now reached $189.83 million.
Let’s look at the performance matrix of the company that is accounted for 730 employees. In terms of profitability, gross margin is 96.95%, operating margin of -547.57%, and the pretax margin is -528.55%.
BridgeBio Pharma Inc (BBIO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BridgeBio Pharma Inc is 18.39%, while institutional ownership is 85.69%. The most recent insider transaction that took place on May 12 ’25, was worth 205,200,000. In this transaction 10% Owner of this company sold 6,000,000 shares at a rate of $34.20, taking the stock ownership to the 13,260,971 shares. Before that another transaction happened on May 12 ’25, when Company’s Affiliate proposed sale 6,000,000 for $35.68, making the entire transaction worth $214,080,000.
BridgeBio Pharma Inc (BBIO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -7.21% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Check out the current performance indicators for BridgeBio Pharma Inc (BBIO). In the past quarter, the stock posted a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.53, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -1.95 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Inc (NASDAQ: BBIO) saw its 5-day average volume 3.54 million, a positive change from its year-to-date volume of 3.13 million. As of the previous 9 days, the stock’s Stochastic %D was 14.98%. Additionally, its Average True Range was 1.61.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 57.84%, which indicates a significant increase from 14.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.25% in the past 14 days, which was lower than the 58.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.40, while its 200-day Moving Average is $29.72. Nevertheless, the first resistance level for the watch stands at $34.14 in the near term. At $34.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $34.73. If the price goes on to break the first support level at $33.55, it is likely to go to the next support level at $33.27. The third support level lies at $32.96 if the price breaches the second support level.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are currently 189,881K shares outstanding in the company with a market cap of 6.43 billion. Presently, the company’s annual sales total 221,900 K according to its annual income of -535,760 K. Last quarter, the company’s sales amounted to 116,630 K and its income totaled -167,420 K.
